Marksans Pharma
227.75
-3.85(-1.66%)
Market Cap₹10,498.20 Cr
PE Ratio27.63
IndustryHealthcare
Company Performance:
1D-1.66%
1M-7.79%
6M-2.15%
1Y+13.30%
5Y+562.06%
View Company Insightsright
Latest news about Marksans Pharma
Marksans Pharma Re-appoints Mark Saldanha as Managing Director for Five-Year Term 1 day ago Yesterday
Marksans Pharma Limited has announced the re-appointment of Mark Saldanha as Managing Director for another five-year term, starting October 6, 2025, subject to shareholder approval. Saldanha, with over 24 years of industry experience, will receive an annual remuneration of Rs. 6,00,00,000.00, including a monthly basic salary of Rs. 40,00,000.00. The decision, recommended by the Nomination and Remuneration Committee, aligns with the company's corporate governance practices. Shareholders will vote on this at the 33rd Annual General Meeting on August 8, 2025.
Marksans Pharma Receives FDA Clearance for Time-Cap Laboratories Facility Jun 30, 2025
Marksans Pharma's UK Unit Secures Approval for Bladder Medication Jun 19, 2025
Marksans Pharma: UK Regulator Approves Subsidiary's Diabetes Medication May 30, 2025
Marksans Pharma Reports Q4 Growth: EBITDA and Net Profit Rise May 19, 2025
More news about Marksans Pharma
19May 25
Marksans Pharma's UK Subsidiary Secures Approval for Sennosides Tablets, Shares Surge
Marksans Pharma Limited's UK subsidiary, Relonchem Limited, has received marketing authorization from the UK Medicines & Healthcare Products Regulatory Agency (MHRA) for Sennosides 7.5 mg Tablets. The company also recently obtained approval for Gabapentin oral solution. These approvals are expected to strengthen Marksans Pharma's position in the UK pharmaceutical market. The company's shares gained over 6% following the announcement.
15May 25
Marksans Pharma's UK Subsidiary Secures Marketing Authorization for Gabapentin Oral Solution
Marksans Pharma Limited's UK subsidiary, Relonchem Ltd, has received marketing authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Gabapentin 50 mg/ml oral solution. This approval allows the company to market and sell the medication in the UK, potentially expanding its presence in the Central Nervous System (CNS) disorders treatment market. Gabapentin is used to treat conditions such as epilepsy, neuropathic pain, and certain anxiety disorders. The oral solution format may improve accessibility for patients who have difficulty swallowing tablets or capsules.
20Mar 25
Marksans Pharma Expands Global Reach: Goa Facility Approved by Australian TGA
Marksans Pharma Limited's manufacturing facility in Goa has received approval from the Australian Therapeutic Goods Administration (TGA) for producing pharmaceutical formulations for Australian markets. The approval covers solid dosage forms including tablets and hard capsules. This milestone enhances the company's global manufacturing footprint, which now includes facilities approved by USFDA, UKMHRA, and Australian TGA. The company plans to distribute products in Australia through its subsidiary, Nova Pharmaceuticals Australasia Pty Ltd. Additionally, Marksans Pharma's UK subsidiary recently received Marketing Authorization from UK MHRA for Baclofen 10 mg Tablets.
19Mar 25
Marksans Pharma's UK Arm Secures MHRA Approval for Baclofen Tablets
Marksans Pharma Limited's UK subsidiary, Relonchem Limited, has received Marketing Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) for Baclofen 10mg tablets. Baclofen is used to treat muscle spasticity in conditions like multiple sclerosis and spinal cord injuries. This approval is expected to strengthen Marksans Pharma's position in the UK pharmaceutical market and contribute to its revenue growth.
25Feb 25
Marksans Pharma's UK Arm Secures Marketing Nod for Dual Action Pain Relief Tablets
Marksans Pharma's UK subsidiary, Relonchem Limited, has received marketing authorization for Ibuprofen and Paracetamol 200 mg/500 mg film-coated tablets in the UK. The product will be marketed as Bell's Healthcare Dual Action Pain Relief tablets. This approval aligns with Marksans' expansion strategy in the UK market, where the company aims to double its revenue within 5-7 years. Marksans reported strong Q3 FY2025 results with 16.3% YoY revenue growth to INR 682 crores, including 37.1% growth in the US market and 2.6% growth in the UK & EU. The company has 34 products awaiting approval in the UK and is targeting overall revenue of INR 3,000 crores in the near term.
Marksans Pharma
227.75
-3.85
(-1.66%)
1 Year Returns:+13.30%
Industry Peers
Sun Pharmaceutical
1,699.00
(+0.41%)
Divis Laboratories
6,616.50
(-0.03%)
Cipla
1,532.50
(+3.00%)
Torrent Pharmaceuticals
3,603.80
(+2.38%)
Mankind Pharma
2,603.40
(+0.54%)
Dr Reddys Laboratories
1,277.90
(+0.98%)
Zydus Life Science
976.40
(+0.53%)
Lupin
1,951.00
(+0.49%)
Abbott
33,780.00
(-2.31%)
Aurobindo Pharma
1,122.80
(+0.78%)